£4.3m boost for Oxford-Glasgow spinout tackling antimicrobial resistance

Glox Therapeutics, a company pioneering the development of precision antibiotics to combat antimicrobial resistance, has raised £4.3M in early-stage funding to develop effective targeted therapeutics against antibiotic-resistant gram-negative bacteria


Professor Colin Kleanthous

Professor Colin Kleanthous

Antimicrobial resistance (AMR) is a major public health crisis throughout the world. It is estimated that around 1.27 million people per year die as a result of AMR due to the therapeutic failure of available antibiotics.

By 2050, AMR is predicted to surpass 10 million deaths globally per year at a cost of $100 trillion, and there is an urgent need to develop new effective antimicrobial therapeutics.

Glox Therapeutics is developing precision antibiotics by using engineered protein bacteriocins. These novel antimicrobials exhibit remarkable potency and specificity, enabling them to effectively and selectively target gram-negative pathogens that have already developed AMR.

Professor Colin Kleanthous FMedSci, Iveagh Professor of Microbial Biochemistry at the University of Oxford Department of Biochemistry, co-founded Glox Therapeutics with Professor Daniel Walker from the University of Glasgow (now at the University of Strathclyde) and Dr James Clark, who has held several leadership roles in precision medicine and drug development companies.

Read the full article here: